Dr. Marshall Glesby

Patients with HIV had similar treatment outcomes to patients without HIV when treated for mpox with an antiviral drug called tecovirimat.

Weill Cornell Medicine has been awarded a five-year, $7.8 million grant from the National Heart, Lung, and Blood Institute, part of the National Institutes of Health, to study whether the antibiotic doxycycline may slow the progression of the chronic lung disease emphysema in people living with well-controlled HIV.

A patient living with HIV who received a blood stem cell transplant for high-risk acute myeloid leukemia has been free of the virus for 14 months after stopping HIV antiretroviral drug treatment, suggesting a cure, according to the Weill Cornell Medicine physician-scientists who performed the transplant and managed her care.

Convalescent plasma did not reduce the risk of intubation or death for hospitalized COVID-19 patients in a large, international clinical trial conducted by Weill Cornell Medicine and NewYork-Presbyterian investigators in collaboration with lead investigators at McMaster University.

As doctors face the novel coronavirus that causes COVID-19 with a very limited arsenal of treatments, physicians at Weill Cornell Medicine and NewYork-Presbyterian have rapidly mobilized to test candidate drugs in clinical trials.

As therapies for HIV infection have advanced to help many patients control the infection as a chronic disease, investigators and patients have set their sights on a new goal—finding a cure.